A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...

Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients might ...

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

This news is rather optimistic as schizophrenia has a very high mortality risk. “It’s one of the highest across psychiatric disorders and patients’ lives are shortened on average by about 15 to 20 ...

Bristol Myers Squibb (BMY) ended the recent trading session at $48.59, demonstrating a -1.4% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain ...

Credit: Alphavector via Shutterstock. As the approval date for Bristol Myers Squibb’s (BMS) schizophrenia drug KarXT (xanomeline-trospium) fast approaches, the schizophrenia field eagerly anticipates ...